Q-omics provides the consensus-scored FLT1P1 profile across patient tissues and cancer cell-line models. FLT1P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FLT1P1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FLT1P1 RNA expression shows 14,721 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where FLT1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLT1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLT1P1 survival associations across molecular data types. FLT1P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLT1P1 RNA expression–survival associations across cancer types. High FLT1P1 expression shows unfavorable associations in CHOL, BRCA, UCEC and BLCA, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FLT1P1 RNA expression.
This table summarizes FLT1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FLT1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLT1P1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, LUAD, STAD and KIRP. The KIRC box plot shows higher FLT1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p < 0.001).
This table shows molecular features associated with FLT1P1 in patient tissues and cancer cell lines. In patient samples, FLT1P1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
